16 January 2026
16 January 2026
Eli Lilly has further expanded its weight-loss initiatives with novel therapies such as orforglipron, an oral GLP-1 receptor agonist.
The sale price marks an inflection in voucher market value over recent years.
Presenting at the conference, Dr Chen discussed their highly integrated and holistic CDRMO+ platform.
The ‘KojoX’ method of cloning facilities around the globe keeps the CDMO agile in an industry fractured by geopolitical strife.
The funding aims to encourage innovation in Europe amid concerns that innovation across the continent is lagging behind China and the US.
The joint guidance was created to ensure drug developers employ best practices when using AI.
To thrive beyond rare disease, cell and gene therapy developers must scale-up manufacturing and commercialisation.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
